

# Jose Martinez-Raga

## List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/3763286/publications.pdf](https://exaly.com/author-pdf/3763286/publications.pdf)

Version: 2025-02-01

64  
papers

38,261  
citations

139253

30  
h-index

107390

61  
g-index

76  
all docs

76  
docs citations

76  
times ranked

68322  
citing authors

#	ARTICLE	IF	CITATIONS
1	Autistic Children/Adolescents Have Lower Adherence to the Mediterranean Diet and Higher Salivary IL-6 Concentration: Potential Dietâ€™Inflammation Links?. Pathophysiology, 2024, 31, 376-387.	2.5	0
2	Circadian Disruption and Mental Health: The Chronotherapeutic Potential of Microbiome-Based and Dietary Strategies. International Journal of Molecular Sciences, 2023, 24, 7579.	4.5	17
3	A Feasibility Study of Patients with Major Depression and Substance Use Disorders: Vortioxetine as Maintenance Treatment. Neuropsychiatric Disease and Treatment, 2022, Volume 18, 965-976.	2.5	4
4	Structure and Functioning of Acute Inpatient Psychiatric Units in Spain: Qualitative Study. JMIR Research Protocols, 2021, 10, e26214.	1.4	0
5	Subgroups of Children with Autism Spectrum Disorder without Intellectual Disability: A Longitudinal Examination of Executive and Socio-Adaptive Behaviors in Adolescence. Journal of Clinical Medicine, 2021, 10, 2220.	2.6	5
6	Developmental outcomes in adolescence of children with autism spectrum disorder without intellectual disability: A systematic review of prospective studies. Neuroscience and Biobehavioral Reviews, 2021, 126, 590-603.	7.3	7
7	Empirical examination of executive functioning, ADHD associated behaviors, and functional impairments in adults with persistent ADHD, remittent ADHD, and without ADHD. BMC Psychiatry, 2020, 20, .	3.4	31
8	Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study. Drugs - Real World Outcomes, 2020, 7, 75-83.	1.6	20
9	Large expert-curated database for benchmarking document similarity detection in biomedical literature search. Database: the Journal of Biological Databases and Curation, 2019, 2019, .	3.0	15
10	Global, regional, and national age-sex-specific mortality and life expectancy, 1950â€™2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1684-1735.	35.3	754
11	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet, The, 2018, 391, 2236-2271.	35.3	674
12	1st International Expertsâ€™ Meeting on Agitation: Conclusions Regarding the Current and Ideal Management Paradigm of Agitation. Frontiers in Psychiatry, 2018, 9, .	2.7	34
13	La carga de enfermedad en EspaÃ±a: resultados del Estudio de la Carga Global de las Enfermedades 2016. Medicina ClÃ¡nica, 2018, 151, 171-190.	0.8	124
14	Health care and societal costs of the management of children and adolescents with attention-deficit/hyperactivity disorder in Spain: a descriptive analysis. BMC Psychiatry, 2018, 18, .	3.4	38
15	Alcohol use and burden for 195 countries and territories, 1990â€™2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2018, 392, 1015-1035.	35.3	2,234
16	Chronic hepatitis C and individuals with a history of injecting drugs in Spain: population assessment, challenges for successful treatment. European Journal of Gastroenterology and Hepatology, 2017, 29, 629-633.	1.4	25
17	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990â€™2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet, The, 2017, 390, 231-266.	35.3	510
18	Smoking prevalence and attributable disease burden in 195 countries and territories, 1990â€™2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet, The, 2017, 389, 1885-1906.	35.3	1,302

#	ARTICLE	IF	CITATIONS
19	Attention-deficit hyperactivity disorder medication use: factors involved in prescribing, safety aspects and outcomes. <i>Therapeutic Advances in Drug Safety</i> , 2017, 8, 87-99.	2.8	28
20	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1084-1150.	35.3	572
21	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1260-1344.	35.3	1,580
22	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1151-1210.	35.3	3,658
23	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1211-1259.	35.3	5,825
24	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1345-1422.	35.3	1,929
25	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1423-1459.	35.3	285
26	The Role of Education on Dual Disorders: A Discussion Paper. <i>Addictive Disorders and Their Treatment</i> , 2017, 16, 155-163.	0.6	0
27	Joint statement on dual disorders: Addiction and other mental disorders. <i>Salud Mental</i> , 2017, 40, 245-247.	0.6	11
28	Hepatitis C CrÃ³nica y usuarios con un historial de inyecciÃ³n de drogas en EspaÃ±a: evaluaciÃ³n de la poblaciÃ³n, retos para un tratamiento efectivo.. <i>Revista De Psicología De La Salud</i> , 2017, 29, 71.	0.9	9
29	Nonmedical use of prescription drugs in the European Union. <i>BMC Psychiatry</i> , 2016, 16, .	3.4	139
30	State of Training, Clinical Services, and Research on Dual Disorders Across France, India, Israel, and Spain. <i>Journal of Dual Diagnosis</i> , 2016, 12, 252-260.	2.2	10
31	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1603-1658.	35.3	1,604
32	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1459-1544.	35.3	4,883
33	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1545-1602.	35.3	5,331
34	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1659-1724.	35.3	4,241
35	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1725-1774.	35.3	584
36	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1813-1850.	35.3	427

#	ARTICLE	IF	CITATIONS
37	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980â€“2015: the Global Burden of Disease Study 2015. <i>Lancet HIV</i> , 2016, 3, e361-e387.	8.2	452
38	Novel psychoactive substance use in the European Union. <i>Drug and Alcohol Dependence</i> , 2015, 156, e165.	3.1	0
39	Who says this is a modern disorder? The early history of attention deficit hyperactivity disorder. <i>World Journal of Psychiatry</i> , 2015, 5, 379.	3.1	19
40	Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2015, , 1359.	2.5	12
41	Attention-deficit hyperactivity disorder (ADHD), substance use disorders, and criminality: a difficult problem with complex solutions. <i>International Journal of Adolescent Medicine and Health</i> , 2015, 27, 163-175.	1.8	47
42	Editorial. <i>Advances in Dual Diagnosis</i> , 2015, 8, .	0.9	5
43	Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder. <i>OncoTargets and Therapy</i> , 2015, , 1359.	1.6	0
44	Dual Diagnosis Resource Needs in Spain: A National Survey of Professionals. <i>Journal of Dual Diagnosis</i> , 2014, 10, 84-90.	2.2	15
45	Professionalsâ€™ perceptions about healthcare resources for co-occurring disorders in Spain. <i>International Journal of Mental Health Systems</i> , 2014, 8, .	3.2	4
46	Attention deficit hyperactivity disorder and dual disorders. Educational needs for an underdiagnosed condition. <i>International Journal of Adolescent Medicine and Health</i> , 2013, 25, 231-243.	1.8	27
47	Rethinking Dual Disorders/Pathology. <i>Addictive Disorders and Their Treatment</i> , 2013, 12, 1-10.	0.6	31
48	Addressing Dual Diagnosis Patients Suffering from Attention-Deficit Hyperactivity Disorders and Comorbid Substance Use Disorders. <i>Addictive Disorders and Their Treatment</i> , 2013, 12, 213-230.	0.6	10
49	Nutritional Education of Secondary Education Students and Diet Quality. , 2013, , 207-218.		0
50	13. Attention-deficit hyperactivity disorder and dual disorders: educational needs for an underdiagnosed condition. , 2013, , 151-172.		0
51	Budgetary impact analysis of buprenorphine-naloxone combination (SuboxoneÂ®) in Spain. <i>Health Economics Review</i> , 2012, 2, .	3.0	5
52	Risk of Serious Cardiovascular Problems with Medications for Attention-Deficit Hyperactivity Disorder. <i>CNS Drugs</i> , 2012, 27, 15-30.	6.8	105
53	Indicadores de calidad asistencial de GESIDA para la atenci3n de personas infectadas por el virus de la inmunodeficiencia adquirida/sida y metadona. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2011, 29, 715-716.	0.8	0
54	Modafinil: A Useful Medication for Cocaine Addiction? Review of the Evidence from Neuropharmacological, Experimental and Clinical Studies. <i>Current Drug Abuse Reviews</i> , 2008, 1, 213-221.	2.0	42

#	ARTICLE	IF	CITATIONS
55	One session of high frequency repetitive transcranial magnetic stimulation (rTMS) to the right prefrontal cortex transiently reduces cocaine craving. <i>Drug and Alcohol Dependence</i> , 2007, 86, 91-94.	3.1	216
56	Add-on gabapentin in the treatment of opiate withdrawal. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2004, 28, 599-601.	4.1	41
57	Anorgasmia in a Patient Treated With Bupropion SR for Smoking Cessation. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 460-461.	2.0	5
58	Atenci3n y craving o ganas compulsivas. Avances en su conceptualizaci3n y su implicaci3n en la prevenci3n de reca3das. <i>Revista De Psicologia De La Salud</i> , 2004, 20, 365.	0.9	4
59	Treatment of nicotine dependence with bupropion SR: review of its efficacy, safety and pharmacological profile. <i>Addiction Biology</i> , 2003, 8, 13-21.	2.7	23
60	UNPLANNED VERSUS PLANNED DISCHARGES FROM IN-PATIENT ALCOHOL DETOXIFICATION: RETROSPECTIVE ANALYSIS OF 470 FIRST-EPISODE ADMISSIONS. <i>Alcohol and Alcoholism</i> , 2002, 37, 277-281.	1.9	66
61	Positive or negative history of childhood sexual abuse among problem drinkers: relationship to substance use disorders and psychiatric co-morbidity. <i>Journal of Substance Use</i> , 2002, 7, 34-40.	1.1	1
62	Hepatitis B and C in alcohol-dependent patients admitted to a UK alcohol inpatient treatment unit. <i>Addiction Biology</i> , 2001, 6, 363-372.	2.7	12
63	What Makes Alcohol-Dependent Individuals Early in Abstinence Crave for Alcohol: Exposure to the Drink, Images of Drinking, or Remembrance of Drinks Past?. <i>Alcoholism: Clinical and Experimental Research</i> , 1998, 22, 1376-1381.	2.7	23
64	Gender differences in cocaine dependent patients: a 6 month follow-up study. <i>Drug and Alcohol Dependence</i> , 1997, 44, 35-40.	3.1	104